Osteoclast-derived coupling factors and exosomal packaging microRNA regulate bone formation and remodelling

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Biological Reviews</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>Draft</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Original Article</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>n/a</td>
</tr>
</tbody>
</table>
| Complete List of Authors: | Zhu, Sipin; Wenzhou Medical University Second Affiliated Hospital, Department of Orthopaedics  
Yao, Felix; University of Western Australia, School of Pathology and Laboratory Medicine  
Qiu, Heng; The University of Western Australia, School of Pathology and Laboratory Medicine  
Zhang, Ge; Hong Kong Baptist University School of Chinese Medicine, Institute for Advancing Translational Medicine in Bone & Joint Diseases  
Xu, Huazi; Wenzhou Medical University Second Affiliated Hospital, Department of Orthopaedics  
Xu, Jiake; The University of Western Australia, The School of Pathology and Laboratory Medicine |
| Keywords: | bone remodelling, osteoblasts, osteoclasts, bone microenvironment, exosomal microRNA, coupling factor, angiogenesis, osteogenesis |
Osteoclast-derived coupling factors and exosomal packaging microRNA regulate bone formation and remodelling

Sipin Zhu\textsuperscript{1,2}, Felix Yao\textsuperscript{2}, Heng Qiu\textsuperscript{2}, Ge Zhang\textsuperscript{3}, Huazi Xu\textsuperscript{1}, Jiake Xu\textsuperscript{1,2,*}

1 Department of Orthopaedics, The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325027 China

2 School of Pathology and Laboratory Medicine, The University of Western Australia, Perth, WA 6009, Australia

3 Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
ABSTRACT

Bone remodelling is a continuous process by which bone resorption by osteoclasts is followed by bone formation by osteoblasts to maintain skeletal homeostasis. These two forces must be tightly coordinated not only quantitatively, but also in time and space, and its malfunction leads to diseases such as osteoporosis. Recent research focusing on the cross-talk and coupling mechanisms associated with the sequential recruitment of osteoblasts to areas where osteoclasts have removed bone matrix have identified a number of osteogenic factors produced by the osteoclasts themselves. Osteoclast-derived factors and exosomal containing miRNA can either enhance or inhibit osteoblast differentiation through paracrine and juxtacrine mechanisms, and therefore may have a central coupling role in bone formation. Entwined with angiocrine factors released by vessel-specific endothelial cells and perivascular cells or pericytes, these factors play a critical role in angiogenesis-osteogenesis coupling essential in bone remodelling.

Key words: bone remodelling, osteoblasts, osteoclasts, bone microenvironment, exosomal microRNA, coupling factor, angiogenesis, osteogenesis
CONTENTS

I. Introduction ................................................................. 4

II. The bone remodelling unit and cycle ................................ 6
(1) Initiation phase .......................................................... 7
(2) Reversal phase .......................................................... 7
(3) Termination phase ....................................................... 7

III. Osteoclast derived coupling factors ............................... 8
(1) Matrix-derived factors ................................................ 8
(2) Osteoclast –secreted factors: a paracrine mechanism .......... 9
(3) Osteoclast membrane bound factors: a juxtacrine mechanism 10
(4) Osteoclast-derived exosomal packaging microRNA .......... 11

IV. Other local factors that affect bone remodelling ............... 11

V. Conclusions ................................................................. 13

VI. Acknowledgements ...................................................... 14

VII. References ................................................................. 15
I. INTRODUCTION

The skeleton is a metabolically active organ that undertakes constant remodelling throughout life to maintain its structural integrity and calcium homeostasis. Bone remodelling relies on the accurate balance between bone resorption by osteoclasts and bone matrix formation by mesenchymal lineage osteoblasts, and involves a complex series of sequential steps that are highly regulated. The group of cells actively participating in remodelling is designated as the basic multicellular unit (BMU) (Kular, Tickner, Chim et al., 2012; Sims & Walsh, 2012). The cellular activities in each BMU aims to achieve a correct balance between osteoblast and osteoclast activity in response to osteoclastic bone resorption, designated “coupling”, to maintain a balanced bone mass. When this coupling is interrupted, the accurate bone mass could be compromised, leading to skeletal disorders such as osteoporosis and osteopetrosis. A greater understanding of the mechanisms underlying coupling between the osteoclast and osteoblast coordination in bone remodelling may open a new avenue to identifying target molecules for alternative therapies more efficacious against these bone disorders.

The BMU consists of cells that contribute signalling pathways to bone resorption (osteoclast) or bone formation (osteoblast), and include osteocytes, T-cells, macrophages, pericytes, vascular endothelial cells, canopy bone lining cells, and precursor populations of osteoblasts and osteoclasts (Kular et al., 2012; Sims et al., 2012) (Fig. 1). Bone remodelling is known to be regulated by both local and systemic factors, which include parathyroid hormone (PTH), calcitriol, hormones (such as thyroid hormone, growth hormone, sex hormone, and glucocorticoids), and growth factors (such as insulin-like growth factors (IGFs), tumour growth factor-beta (TGF-beta), bone morphogenetic proteins (BMP), and prostaglandins). Furthermore, it is well established that osteoblastic like cells govern the
formation and function of osteoclasts through the osteoprotegerin (OPG) / receptor activator
of NF-kappa B ligand (RANKL) / RANK axis (Kong, Yoshida, Sarosi et al., 1999).

Emerging evidence points to the involvement of factors derived from osteoclasts
themselves in the coupling process (Sims & Martin, 2014a; Sims & Martin, 2015). For
instance, studies have found that complete inhibition of both osteoclast formation and
function by Denosumab, a humanised anti-RANKL antibody, leads to the reduction of bone
formation secondary to reduced osteoblast activity because of the loss of osteoclast-derived
coupling factors that serve to stimulate bone formation (Kostenuik, Nguyen, McCabe et al.,
2009). Further, the inhibition of both osteoclast formation and function by long-term
bisphosphonate use is linked to the occurrence of osteonecrosis of the jaw (ONJ) (Reyes, Hitz,
Prieto-Alhambra et al., 2016) or atypical sub-trochanteric femoral fractures (Miller &
McCarthy, 2015) due to its adverse effects on bone remodelling, resulting from decreased
bone formation. In comparison, inhibition of bone resorption function without affecting its
differentiation by Odanacatib (ODN), a selective and reversible inhibitor of cathepsin K, does
not cause the reduction of bone formation. In fact, bone formation was preserved at certain
skeletal sites (Sims & Ng, 2014b). It appears that ODN prevents the degradation of matrix-
derived proteins in supernatants of osteoclasts, including IGF-I, and BMP-2 (Fuller,
Lawrence, Ross et al., 2008). This preservation of bone formation appears to be due to the
effects of coupling factors secreted by osteoclasts and released from demineralised bone
matrix. This indicates that bone resorptive activities of osteoclasts are separable from their
coupling activities.

This review aims to provide an exploration of coupling factors and mechanism of
cross talks between the osteoclast and osteoblast, and to relate their functionality to
uncoupling consequences in pathological bone and joint diseases. The regulatory mechanisms
of osteoblast-directed osteoclastic bone resorption is well documented, however there is
accumulating evidence to indicate that osteoclasts are also conversely controlling osteoblastic bone formation. Dissecting the molecular mechanisms that regulate the function of coupling factors in bone remodelling will give insight into potential future therapies for these bone diseases.

II. THE BONE REMODELLING UNIT AND CYCLE

Bone remodelling takes place within anatomically distinct sites within the skeleton termed basic multicellular unit (BMU) which comprises a tightly regulated cohort of cells (Kular et al., 2012; Sims et al., 2012) (Fig. 1). During this process unwanted or damaged bone is resorbed by osteoclasts and replaced with new bone by osteoblasts at the approximately same location, to maintain bone mass at the same level during adult life. This is distinct from bone modelling where bone formation occurs at sites that have not been marked by osteoclastic resorption, resulting in a transformation in the size, shape or micro-architecture of the bone.

Bone remodelling is a multicellular event involving osteoprogenitors on the bone surface, capillary blood supply, mesenchymal envelope like canopy cells surrounding the bone marrow, and within the bone matrix itself (Fig. 1). These multiple cell types communicate or cross talk with each other, and are essential for proper bone development and homeostasis (Schipani, Wu, Rankin et al., 2013). Evidence indicates that the growth of blood vessels and activity of vascular endothelial growth factor (VEGF) in bone and osteogenesis are also coupled, and is regulated by different capillary subtypes (Clarkin & Gerstenfeld, 2013; Kusumbe, Ramasamy & Adams, 2014). Also recruitment of osteoprogenitors from the canopy onto reversal surfaces is important during bone remodelling (Jensen, Andersen, Hauge et al., 2015).

The bone remodelling cycle is accomplished according to three distinct sequential phases (Fig. 2).
(1) Initiation Phase

During the Initiation Phase, there is recruitment of osteoclast precursors to the BMU from hematopoietic precursors, and differentiation of osteoclast precursors into multinucleated osteoclasts. Osteoblasts control of osteoclast differentiation and activation is regulated by osteoblast-expressed molecules such as RANKL, OPG (Sims et al., 2014a; Sims et al., 2015), and Semaphorin 3A (Hayashi, Nakashima, Taniguchi et al., 2012).

(2) Reversal Phase

A Reversal Phase then emerges whereby osteoclast function is subdued via apoptosis or autophagy whereas osteoblast lineage cells are recruited and differentiated. The reversal phase is a transition from osteoclast bone resorption to osteoblast bone formation. There appears to be a gap or delayed period between bone resorption and formation (Sims et al., 2014a; Sims et al., 2015), and coupling mechanisms are employed to overcome this time delay (Fig. 2). Osteoclast-derived factors can directly or indirectly (being refined by other factors) initiate the differentiation of osteoblasts in resorbed sites to form new bone. Other anabolic coupling factors are also released from the resorbed bone matrix and other cell types within the BMU, such as TGF-beta and bidirectional signalling between EphrinB2 on osteoclasts and EphrinB4 on osteoblast precursors might facilitate this transition phase.

(3) Termination Phase

The Termination Phase involves osteoblastic bone formation and mineralization of the bone matrix (Raggatt & Partridge, 2010). The estimated average length of the remodelling phase in human cancellous bone from iliac crest is about 3 weeks for bone resorption and 3-4 months for bone formation (Eriksen, Gundersen, Melsen et al., 1984; Eriksen, Melsen & Mosekilde, 1984), and approximately 5 weeks for reversal phase (Tran Van, Vignery & Baron, 1982). However, the period of the bone remodelling process varies by species and type of bone, and is influenced by the disruption or perturbation of coupling activities in...
pathological conditions such as such as osteoporosis, bone tumors, rheumatoid arthritis, and osteoarthritis.

III. OSTEOCLAST DERIVED COUPLING FACTORS

The concept of “coupling” in the bone remodelling process was first proposed by Frost’s group who observed sites of osteoclastic bone resorption was sequentially replaced by osteoblastic bone formation (Hattner, Epker & Frost, 1965). The increase in bone formation (due to increased number of osteoclasts) observed with the impairment of bone resorption due to a deficiency of the chloride channel ClC-7 or c-src kinase activity (Marzia, Sims, Voit et al., 2000; Schaller, Henriksen, Sveigaard et al., 2004), further suggest that osteoclasts exhibit coupling mechanism to promote osteoblast activity independently of their bone resorbing activity. It is proposed that during osteoclastic bone resorption, coupling factors are produced by osteoclasts to regulate osteoblast activity in the BMU (Table 1). To date, four major classes of osteoclast-derived coupling factors have been reported, which include matrix-derived factors released during osteoclastic bone resorption, osteoclasts secreted factors, osteoclast membrane-bound molecules, and osteoclast-derived exosomal microRNAs (miRNAs) (Fig. 3).

(1) Matrix- derived factors

A number of latent form of growth factors are imbedded into bone matrix during matrix formation, and reactivated during the next cycle of osteoclastic bone resorption (Oreffo, Mundy, Seyedin et al., 1989) (Fig. 3A). These proteins which include TGF-beta (Bownell & Mundy, 1990; Crane & Cao, 2014), BMP-2, platelet-derived growth factor (PDGF) (Tsukamoto, Matsui, Fukase et al., 1991; Xie, Cui, Wang et al., 2014a), and IGFs (Mohan & Baylink, 1996) are also activated by plasmin generated by plasminogen activators (Campbell,
Novak, Yanosick et al., 1992; Yee, Yan, Dominguez et al., 1993) and matrix-metalloproteinases (Dallas, Rosser, Mundy et al., 2002). Howard et al. was one of the earliest to propose that resorption was accompanied by the release of growth factors stored in the bone matrix which contribute to the coupling activities and restoration of bone loss in the BMU (Howard, Bottemiller, Turner et al., 1981). More recently Ota et al. demonstrated that TGF-beta1 induces Wnt10b production in osteoclast to enhance coupling to osteoblasts (Ota, Quint, Ruan et al., 2013a), and CXCL16 and LIF which modulate recruitment of osteoblasts during bone remodelling (Ota, Quint, Weivoda et al., 2013b). In addition, mouse genetic experiments have shown that TGF-beta1 promotes migration of mesenchymal stem cells (MSCs) in bone microenvironment that facilitate the coupling of bone resorption with formation (Tang, Wu, Lei et al., 2009). IGF-1 was also found to promote recruitment of MSCs and osteoblast differentiation (Xian, Wu, Pang et al., 2012). In bone microenvironment, dysregulation of these locally produced factors can contribute to disease condition and progress. For example, dysregulation of TGF-beta alters the fate of MSCs, leading to the bone microarchitecture damage characterised in rheumatoid arthritis (Crane et al., 2014). In bone metastasis, TGF-beta can contribute to a vicious cycle of bone metastasis and bone loss (Juarez & Guise, 2011).

(2) Osteoclast – secreted factors: a paracrine mechanism

A set of secreted factors are produced by osteoclasts, and via a paracrine mode of action, promote osteoblast migration, differentiation, and bone formation in the BMU (Fig. 3B). These secreted factors act as a ligand and bind to their receptors on osteoblasts: cardiotrophin-1 binds with pg130 receptors (Sims & Walsh, 2010; Walker, McGregor, Poulton et al., 2008); sphingosine-1-phosphate (S1P) with S1P1 and S1PR2 receptors (Quint, Ruan, Pederson et al., 2013; Ryu, Kim, Chang et al., 2006); BMP-6 with their specific type-I
and type-II serine/threonine kinase receptors BMPR-I and BMPR-II (Pederson, Ruan, Westendorf et al., 2008); Wnt10b and Dickkopf-related protein 1 (DKK-1) with Frizzled receptors and their co-receptors low-density lipoprotein receptor-related protein -5 (LRP5) or LRP6 (Ota et al., 2013a); CTHRC1 with the Wnt-Fzd/Ror2 receptor complex (Takeshita, Fumoto, Matsuoka et al., 2013; Yamamoto, Nishimura, Misaki et al., 2008), and complement factor 3a (C3a) with the C3a receptor (Matsuoka, Park, Ito et al., 2014). Secreted afamin derived from nonresorbing osteoclast - derived functions as chemokine for preosteoblasts migration via the regulation of Akt-signaling pathway (Kim, Lee, Lee et al., 2012). In contrast, the serine protease HTRA1 (Wu, Chim, Kuek et al., 2014) is a secreted factor released by osteoclasts, and inhibit osteoblast differentiation, suggesting that osteoclasts could produce both negative and positive factors to modulate bone remodelling process.

(3) Osteoclast membrane bound factors: a juxtacrine mechanism

Recent studies indicate that osteoclasts and their precursors can regulate osteoblast formation and functions by means of direct cell-cell contact via cell-surface regulatory proteins (Fig. 3C). EphrinB2 protein expressed by osteoclasts as a cell surface molecule can interact with its receptor EphB4 in osteoblasts and regulate osteoblast differentiation. Interestingly, the EphB4 receptor can signal to EphrinB2 in the reverse direction to suppress the formation of osteoclast precursors (Zhao, Irie, Takada et al., 2006). Thus the bidirectional signalling between the cell-surface ligand EphrinB2 and its receptor EphB4 is important in the regulation of bone absorption and remodelling. Dis-regulation of ephrinB2/EphB4 axis is seen in osteolytic disorder such as multiple myeloma (Pennisi, Ling, Li et al., 2009).

Semaphorin 4D (Sema-4D) is an osteoclast derived molecule that can act through its receptor Plexin-B1 on osteoblasts to inhibit bone formation (Negishi-Koga, Shinohara, Komatsu et al., 2011). Antibody treatment specific to Sema-4D markedly prevented bone
loss in a model of postmenopausal osteoporosis (Negishi-Koga et al., 2011), and its inhibition partly counteracts alveolar bone loss caused by osteoporosis (Zhang, Wei, Miron et al., 2014) and lytic skeletal metastases associated with breast cancers and other epithelial malignancies which overexpress Sema-4D (Yang, Buhamrah, Schneider et al., 2016). Taken together, targeting Sema-4D might represent a new therapy to cancers - induced osteolytic conditions.

(4) Osteoclast-derived exosomal packaging microRNA

Osteoclast-derived exosomal microRNAs (miRNAs) represents a new class of osteoclast-released coupling factor. MicroRNAs are small noncoding RNA molecules containing ~22 nucleotides that regulate gene expression and versatile biological processes (Rigoutsos & Furnari, 2010). A series of miRNAs has been characterised to regulate osteoblastic bone formation, and the dysregulation of these miRNAs affects skeletal health (Lian, Stein, van Wijnen et al., 2012). Exosomal-containing miR-214-3p (Li, Liu, Guo et al., 2016; Sun, Zhao, Li et al., 2016) are osteoclast-derived inhibitors of osteoblast differentiation and bone formation. Increased osteoclastic miR-214-3p is associated with reduced bone formation in elderly women with fractures and in ovariectomized mice (Li et al., 2016) (Fig. 3D) In vitro and in vivo studies have identified that osteoclast-derived exosomal miR-214-3p can negatively impact osteoblastic bone formation, suggesting a model of paracrine action (Li et al., 2016; Sun et al., 2016). Thus, inhibition of osteoclast - derived miR-214-3p can promote bone anabolic action, and has therapeutic potential.

IV. OTHER LOCAL FACTORS THAT AFFECT BONE REMODELLING

Osteogenesis during bone remodelling is coupled with angiogenesis for nutrient supply and help further couple bone resorption and bone formation (Figs 1 and 2). PDGF-BB secreted by preosteoclasts stimulates proliferation and migration of both endothelia progenitor cells
(EPCs) and MSCs, and induces CD31 and endomucin (CD31(hi)Emcn(hi)) vessel formation during bone remodelling, thus coupling angiogenesis and osteogenesis (Xie, Cui, Wang et al., 2014b). PDGF-BB secreted by osteoclasts influences the temporal-spatial vessel formation for new bone formation involving stabilising newly formed vessels, mobilising mesenchymal stem cells, and promoting osteoblast differentiation (Ramasamy, Kusumbe, Wang et al., 2014; Xie et al., 2014a). Other secreted factors of the adipogenic signaling molecules such as leptin, and adiponectin could also affect bone microenvironment by altering bone marrow adipocytes, which might lead to impaired vascular and osteogenesis (Muruganandan & Sinal, 2014).

Angiocrine factors such as Noggin mediates endothelial-cell-specific Notch pathway and osteogenesis (Kusumbe et al., 2014; Ramasamy et al., 2014). Further, Notch signalling in endothelial cells can regulate hematopoietic stem cell niches via CD31-positive capillaries and PDGFR-B-positive perivascular cells (Kusumbe, Ramasamy, Itkin et al., 2016). Epidermal growth factor-like domain 7 (EGFL7) which is expressed in osteoclasts and osteoblasts is an antagonist to the Notch pathway (Schmidt, Bicker, Nikolic et al., 2009), and regulates endothelial cell migration and angiogenesis (Chim, Kuek, Chow et al., 2015; Chim, Tickner, Chow et al., 2013). In addition, EGFL6 and Nephronectin (NPNT) expressed osteoblasts regulate angiogenesis by a paracrine mechanism in bone microenvironment (Chim, Qin, Tickner et al., 2011; Kuek, Yang, Chim et al., 2016). Interestingly, NPNT and CD31 expression is reduced in bone of ovariectomised mice and in osteoporosis patients (Kuek et al., 2016). It is likely that exosomal-containing microRNA released from osteoclasts and osteoblasts could also regulate angiogenesis in the bone microenvironment. Identification of novel angiogenic and angiocrine factors that regulate trabecular bone mass and angiogenesis in bone microenvironment will be a future subject of investigation.
V. CONCLUSIONS

1. Bone is a dynamic tissue that undergoes life-long remodelling regulated by the tight coupling of bone resorption and bone formation.

2. During bone remodelling, osteoclast bone resorption and osteoblast bone formation occur independently.

3. Osteoclast-derived factors and exosomal packaging miRNA can either be inhibitory or promote osteogenesis, and emerging evidence indicates that osteoclasts regulate osteoblast bone formation independent of resorptive activity.

4. Osteogenesis in bone remodelling is coupled with angiogenesis. Factors released by preosteoclasts and osteoclasts are able to temporally and spatially coordinate angiogenesis during bone growth and remodelling.

5. It is remarkable that with so many contributors involved in the coupling process, that a genetic error of a single participant leads to pathological processes secondary to altered bone remodelling – when it might be reasonable to expect compensatory mechanisms would normalise the balance in the BMU.

6. The pathways involved in bone remodelling is far more complex than our current understanding, and new insight into coupling mechanisms will help to translate these factors into novel therapeutic approaches for the treatment of bone diseases.

7. However, much work remains to be done to fully understand the nature and significance of the individual factors involved in coupling, the interplay between the many contributors, time- and dose-specific effects of each factor, and their regulation during bone growth and pathology.
VI. ACKNOWLEDGEMENT

This study was also supported in part by the Australian National Health and Medical Research Council (NHMRC, No 1107828), University of Western Australia Research Collaboration Awards. This work is supported by a grant Zhejiang Provincial Natural Science Foundation of China (LY14H170002), the Opening Project of Zhejiang Provincial Top Key Discipline of Clinical Medicine (no. LKFJ017), which in part support Dr. Sipin Zhu as visiting scholar to UWA from Wenzhou Medical University. Dr. Sipin Zhu and Jiake Xu made mutual collaborative visits in 2016.
VII. REFERENCES


Sims N. A. & Martin, T. J. (2015). Coupling Signals between the Osteoclast and Osteoblast: How are Messages Transmitted Between These Temporary Visitors to the Bone Surface? Front Endocrinol (Lausanne) 6, 41.


FIGURE LEGENDS

Figure 1. Schematic diagram showing cells in the basic multicellular units cells that contribute to the bone remodelling in bone microenvironment.

Figure 2. Schematic diagram showing three phases of bone remodelling processes, including initiation phase, reversal phase and termination phase. Note that a cross-talk between osteoclasts and osteoblasts involves a wide variety of cells existing in BMU. (1) Some factors released by osteoclasts are imbedded in bone matrix and may have a direct impact on osteoblasts or regulate osteocytes to modulate the activity of bone formation at resorbing compartments. (2) A direct communication between osteoclasts and osteoblasts during the phase of bone remodeling. (3) Mesenchymal stem cells are also plausible targets for osteoclast-derived coupling factors to modulate resorbed bone formation. (4) Endothelial cells act as important intermediates to deliver coupling signals from osteoclast precursors to osteoblastic osteogenesis.

Figure 3. Schematic diagrams showing 4 common modes of coupling factors by osteoclasts that regulate osteoblast activities, including (A) matrix-derived factors released during osteoclastic bone resorption, (B) soluble factors synthesised and secreted by osteoclasts, (C) factors expressed as membrane-bound proteins on the osteoclast cell surface, and (D) osteoclast-derived exosomal microRNAs (miRNAs) that influence osteogenesis.
Figure 1. Schematic diagram showing cells in the basic multicellular units cells that contribute to the bone remodelling in bone microenvironment.
Figure 2. Schematic diagram showing three phases of bone remodelling processes, including initiation phase, reversal phase and termination phase. Note that a cross-talk between osteoclasts and osteoblasts involves a wide variety of cells existing in BMU. (1) Some factors released by osteoclasts are imbedded in bone matrix and may have a direct impact on osteoblasts or regulate osteocytes to modulate the activity of bone formation at resorbing compartments. (2) A direct communication between osteoclasts and osteoblasts during the phase of bone remodeling. (3) Mesenchymal stem cells are also plausible targets for osteoclast-derived coupling factors to modulate resorbed bone formation. (4) Endothelial cells act as important intermediates to deliver coupling signals from osteoclast precursors to osteoblastic osteogenesis.
Figure 3. Schematic diagrams showing 4 common modes of coupling factors by osteoclasts that regulate osteoblast activities, including (A) matrix-derived factors released during osteoclastic bone resorption, (B) soluble factors synthesised and secreted by osteoclasts, (C) factors expressed as membrane-bound proteins on the osteoclast cell surface, and (D) osteoclast-derived exosomal microRNAs (miRNAs) that influence osteogenesis.

Figure 3
338x190mm (96 x 96 DPI)
Table 1. Examples of osteoclast-derived coupling factors and their potential actions

<table>
<thead>
<tr>
<th>Coupling factors</th>
<th>Derived from</th>
<th>Targeting on</th>
<th>Secreted or Membrane bound</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGF-1 (IGF-2)</td>
<td>Bone matrix</td>
<td>Inhibit osteoclasts</td>
<td>Matrix derived secreted</td>
<td>(25)</td>
</tr>
<tr>
<td>PDGF</td>
<td>Bone matrix</td>
<td>Promote osteoblast migration and proliferation</td>
<td>Matrix derived secreted</td>
<td>(26)</td>
</tr>
<tr>
<td>BMP8</td>
<td>Osteoclasts</td>
<td>Promote osteoblast differentiation</td>
<td>Secreted</td>
<td>(42)</td>
</tr>
<tr>
<td>Complement component 3a</td>
<td>Osteoclasts</td>
<td>Promote osteoblast differentiation</td>
<td>Secreted</td>
<td>(45)</td>
</tr>
<tr>
<td>CT-HRG1</td>
<td>Osteoclasts</td>
<td>Promote osteoblast differentiation and migration</td>
<td>Secreted</td>
<td>(43)</td>
</tr>
<tr>
<td>Alpinin</td>
<td>Osteoclasts</td>
<td>Promote preosteoblast migration</td>
<td>Secreted</td>
<td>(46)</td>
</tr>
<tr>
<td>CXCL16</td>
<td>Osteoclasts</td>
<td>Promote osteoblast migration</td>
<td>Secreted</td>
<td>(34)</td>
</tr>
<tr>
<td>Wnt10b</td>
<td>Osteoclasts</td>
<td>Promote osteoblast mineralization</td>
<td>Secreted</td>
<td>(33)</td>
</tr>
<tr>
<td>Cardiotrophin-1</td>
<td>Osteoclasts</td>
<td>Promote osteoblast activity and mineralization</td>
<td>Secreted</td>
<td>(39)</td>
</tr>
<tr>
<td>HTRA1</td>
<td>Osteoclasts</td>
<td>Inhibit osteoclasts</td>
<td>Secreted</td>
<td>(47)</td>
</tr>
<tr>
<td>PDGF-AB</td>
<td>Preosteoclasts</td>
<td>Promote CD31(hi),Emcn(hi) endothelial cells</td>
<td>Secreted</td>
<td>(26)</td>
</tr>
</tbody>
</table>